Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001GlobeNewsWire • 06/02/25
Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash RunwayGlobeNewsWire • 05/13/25
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual MeetingGlobeNewsWire • 04/29/25
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial ResultsGlobeNewsWire • 03/20/25
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)Zacks Investment Research • 01/21/25
Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a TurnaroundZacks Investment Research • 01/20/25
Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)Zacks Investment Research • 01/17/25
Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)Zacks Investment Research • 01/16/25
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 11/15/24
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 05/21/24